Oral GLP-1 pipeline overview — all agents in development
Pinned because it affects plans people have already made, not because it is dramatic. Everything below is what is confirmed as of today.
This post is the record, and it will be edited as things change — with the change noted rather than substituted. If you have something firmer than what is here, a document or a date or a first-hand account, post it and it goes in with credit.
Read it this way:
- What is stated is confirmed; what is uncertain is marked as uncertain
- Anything time-sensitive is worth verifying yourself before you act on it
- The replies below carry the corrections, so read them before asking
Nothing here is advice about your situation, and the situation is still moving.
TrialTracker_MD said:Oral GLP-1 pipeline overview — all agents in development Pinned because it affects plans people have already made, not because it is dramatic.
That is correct as far as it goes, and here is where it stops going. The absorption variability is real, but it partly averages out over weeks — the steady-state trough is less erratic than any single day would suggest. Where it bites is in the first fortnight, when people conclude the tablet does nothing.
TrialTracker_MD said:Oral GLP-1 pipeline overview — all agents in development Pinned because it affects plans people have already made, not because it is dramatic.
I do not accept that the fasting window is a minor inconvenience. Adherence data on daily orals with timing requirements is consistently worse than weekly injections, and a drug you take imperfectly is a lower dose than the one on the box.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsTaking the question as asked, rather than the general version of it. Orforglipron is the more interesting oral story because it is not a peptide at all. Being a small molecule it does not need SNAC, does not need the fasting window, and has oral bioavailability in the tens of percent rather than about one.
FDA_TrackerJim said:The absorption variability is real, but it partly averages out over weeks — the steady-state trough is less erratic than any single day would suggest.
Can confirm the pattern FDA_TrackerJim describes. The OASIS programme put 50mg oral in the same territory as 2.4mg injectable — around 15% mean weight loss — but it needed a dose 20 times larger to get there because almost none of the tablet is absorbed. The dose numbers are not comparable across routes and quoting them side by side confuses people.